Search
Search Results
-
Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
BackgroundTwenty-four-hour treatment options could provide a continuous drug delivery strategy in advanced Parkinson’s disease and can ameliorate...
-
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
Motor and non-motor symptoms (NMS) have a substantial effect on the health-related quality of life (QoL) of patients with Parkinson's disease (PD)....
-
A meta-analysis evaluating effects of the rotigotine in Parkinson’s disease, focusing on sleep disturbances and activities of daily living
BackgroundRotigotine transdermal patch (TP) is a useful dopaminergic medication for Parkinson’s disease (PD). This meta-analysis attempted to...
-
Idiopathic Parkinson’s Disease at the End of Life: A Retrospective Evaluation of Symptom Prevalence, Pharmacological Symptom Management and Transdermal Rotigotine Dosing
BackgroundDistressing symptoms are prevalent in patients with idiopathic Parkinson’s disease, yet little is known about symptom burden and subsequent...
-
Rotigotine Transdermal Patch: A Review in Parkinson’s Disease
Rotigotine (Neupro ® ), a non-ergolinic dopamine agonist (DA), is administered once daily via a transdermal patch (TP) that delivers the drug over a...
-
Impulse control disorders in Parkinson’s disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis
BackgroundThis analysis is the first systematic review and meta-analysis assessing occurrences of ICD in PD patients treated with oral DAs:...
-
Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
In older patients with Parkinson’s disease (PD), the use of dopamine agonists (DA) has been limited due to uncertainties related to their...
-
Impulse Control Disorders in Parkinson’s Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management
Impulse control disorders in Parkinson’s disease are relatively common drug-induced addictive behaviours that are usually triggered by the dopamine...
-
Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson’s...
-
Screening for impulse control disorders in Parkinson’s disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors
IntroductionDopamine agonist (DA) use is considered the main risk factor for impulse control disorder (ICD) development in Parkinson’s disease (PD)....
-
A novel clinical sign to assess the risk of Parkinson’s disease in patients with isolated asymmetric arm swing
IntroductionAn isolated asymmetric arm swing can represent the beginning of Parkinson’s disease (PD) but also be related to physiological or...
-
Diagnosis and treatment of Parkinson´s disease (guideline of the German Society for Neurology)
IntroductionThe aim of this German national guideline is to optimize the clinical care of patients with Parkinson's disease (PD) in terms of...
-
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?
The standard of care is a term that refers to the level of care, skill, and treatment that a healthcare provider should offer to a patient based on...
-
Implications of dopaminergic medication withdrawal in Parkinson’s disease
The trajectory of the use of dopamine replacement therapy (DRT) in Parkinson’s disease (PD) is variable and doses may need to be increased, but also...
-
Effects of dopaminergic therapy on sleep quality in fluctuating Parkinson’s disease patients
BackgroundSleep disorders negatively impact quality of life in Parkinson’s disease (PD), yet the role of antiparkinsonian drugs on sleep quality is...
-
Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions
Purpose of ReviewParkinson disease dementia (PDD) is a multisystem disorder involving motor and nonmotor symptoms. Therapeutic options for management...